Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study.

ABSTRACT:

Unlabelled

To determine persistence with subcutaneous denosumab every 6 months in women being treated for osteoporosis, we conducted a single-arm prospective, observational study in the United States and Canada. Among 935 patients enrolled, 12-month persistence was 82%, with 66 patients (7%) reporting serious adverse events and 19 patients (2%) reporting fractures.

Introduction

Increased persistence with osteoporosis therapy is associated with reduced fracture risk. Denosumab reduced fracture risk in clinical trials; persistence in community settings is undetermined. This study evaluates persistence with denosumab in community practice in the United States (US) and Canada.

Methods

In a 24-month multicenter, prospective, single-arm, observational study, women being tre

SUBMITTER: Silverman SL 

PROVIDER: S-EPMC4286624 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature